MarketCapTrends
BGMS
Cyclacel Pharmaceuticals, Inc. (BGMS)
NASDAQ

Cyclacel Pharmaceuticals, Inc. Total Liabilities 2009–2025

Cyclacel Pharmaceuticals, Inc. annual/quarterly total liabilities history from 2010 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.

  • Cyclacel Pharmaceuticals, Inc. total liabilities for the quarter ending December 31, 2025 were 1.3M, a 78.57% decrease year-over-year.
  • Cyclacel Pharmaceuticals, Inc. total liabilities for 2025 were 1.3M, a 78.57% decrease from 2024.
  • Cyclacel Pharmaceuticals, Inc. total liabilities for 2024 were 6.3M, a 23.54% decrease from 2023.
  • Cyclacel Pharmaceuticals, Inc. total liabilities for 2023 were 8.2M, a 7.63% increase from 2022.
  • Cyclacel Pharmaceuticals, Inc. total liabilities for 2022 were 7.6M.
Total Liabilities
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Cyclacel Pharmaceuticals, Inc. Annual Total Liabilities (Millions of US $)
2025$1
2024$6
2023$8
2022$8
2021$5
2020$4
2018$5
2017$4
2016$5
2015$6
2014$8
2013$7
2012$9
2011$6
2010$7
Cyclacel Pharmaceuticals, Inc. Quarterly Total Liabilities (Millions of US $)
2025-12-31$1
2024-12-31$6
2023-12-31$8
2022-12-31$8
2021-12-31$5
2020-12-31$4
2018-12-31$5
2017-12-31$4
2016-12-31$5
2015-12-31$6
2014-12-31$8
2013-12-31$7
2012-12-31$9
2011-12-31$6
2010-12-31$7

Cyclacel Pharmaceuticals, Inc. Total Liabilities — FAQ

Cyclacel Pharmaceuticals, Inc. (BGMS) total liabilities over the last 16 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see BGMS's total liabilities history?

The chart and table above show Cyclacel Pharmaceuticals, Inc.'s total liabilities by year and by quarter, including the growth rate.